メディアリリース

November 26, 2018 | Neue Therapiechance bei akute myeloische Leukämie (AML) 

more

October 12, 2018 | Miltenyi Biotec acquires microscopy specialist LaVision BioTec

more

April 1, 2018 | Autolus and Miltenyi Biotec sign strategic supply agreement

more

March 1, 2018 | EMA approves the utilization of the CliniMACS Prodigy® equipment

more

February 1, 2018  |  Cancer coaching for the immune system

more

February 1, 2018  |  Krebs Nachhilfe für das Immunsystem

more

November 2, 2017  |  Cell separation – faster and more reliable than ever

more

September 14, 2017  |  MACSQuant® X revolutionizes high-throughput flow cytometry

more

August 4, 2017  |  Natural killer cells: cultivation, activation, and growth

more

July 3, 2017  |  Miltenyi Biotec named as an employer for the future

more

June 14, 2017  |  MACSprep™ PBMC Isolation Kit, human from Miltenyi Biotec

more

April 20, 2017  |  MACS® GMP T Cell TransAct™ from Miltenyi Biotec

more

January 24, 2017  |  The EU-funded project CARAT offers fellowships for a training course

more

December 8, 2016  |  Reliable and reproducible flow cytometry results

more

November 22, 2016 |  MACS® Academy is starting its new program

more

September 29, 2016 |  Miltenyi Biotec acquires exclusive rights for Vectofusin-1®

more

September 19, 2016 |  CE marked MACS® IVD Antibodies by Miltenyi Biotec

more

July 21, 2016 |  MACSxpress Treg Isolation Kit, human: Quick and efficient

more

August 14, 2014  |  Miltenyi Biotec acquires gene therapy assets from Lentigen Corporation

more

January 24, 2014  |  FDA Approval of CliniMACS® CD34 Reagent System

more

more